S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706)

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 2069-2075

  Ichinose, Yukito ^a   Seto, Takashi ^a   Sasaki, Tomonari ^a   Yamanaka, Takeharu ^a   Okamoto, Isamu ^b   Takeda, Koji ^c   Tanaka, Masahiro ^c   Katakami, Nobuyuki ^d   Sawa, Toshiyuki ^e   Kudoh, Shinzoh ^f   Saka, Hideo ^g   Nishimura, Yasumasa ^b   Nakagawa, Kazuhiko ^b   Fukuoka, Masahiro ^h  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^e Gifu Municipal Hospital   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^h Izumi City Hospital   (Japan)

Author keywords

Cisplatin; Concurrent chemoradiotherapy; Non small cell lung cancer; Phase II trial; S 1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; ESOPHAGITIS; FEMALE; FEVER; HUMAN; JAPAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG COMBINATIONS; ESOPHAGITIS; FEMALE; FEVER; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OXONIC ACID; TEGAFUR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 85028126277     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182307e5a     Document Type: Article

References (28)

1. Pfister, DG, Johnson, DH, Azzoli, CG, et al., American Society of Clinical Oncology, American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004), 330–353.
2. Auperin, A, Le Pechoux, C, Rolland, E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28 (2010), 2181–2190.
3. Ichinose, Y, Nakai, Y, Kudoh, S, et al. Uracil/tegafur plus cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10 (2004), 4369–4373.
4. Curran, W, Scott, C, Langer, C, Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer, 29(93s, suppl), 2000 abstr 303.
5. Furuse, K, Fukuoka, M, Kawahara, M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999), 2692–2699.
6. Kawahara, M, Furuse, K, Segawa, Y, et al., S-1 Cooperative Study Group (Lung Cancer Working Group), Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85 (2001), 939–943.
7. Ichinose, Y, Yoshimori, K, Sakai, H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10 (2004), 7860–7864.
8. Kubota, K, Sakai, H, Yamamoto, N, et al. A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. J Thorac Oncol 5 (2010), 702–706.
9. Ichinose, Y, Takanashi, N, Yano, T, et al. A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer 75 (1995), 2677–2680.
10. Ichinose, Y, Yosimori, K, Yoneda, S, et al. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. Cancer 88 (2000), 318–323.
11. Kubota, K, Watanabe, K, Kunitoh, H, et al., Japanese Taxotere Lung Cancer Study Group, Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22 (2004), 254–261.
12. Ohe, Y, Ohashi, Y, Kubota, K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18 (2007), 317–323.
13. Schiller, JH, Harrington, D, Belani, CP, et al., Eastern Cooperative Oncology Group, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002), 92–98.
14. Okamoto, I, Yoshioka, H, Morita, S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28 (2010), 5240–5246.
15. Byfield, JE, Calabro-Jones, P, Klisak, I, et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and x rays. Int J Radiat Oncol Biol Phys 8 (1982), 1923–1933.
16. Douple, EB, Richmond, RC, Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiat Oncol Biol Phys 8 (1982), 501–503.
17. Gemma, A, Kudoh, S, Yoshimura, A, et al. Pilot trial of a combination comprising of consecutive oral administration of UFT, and two-divided administration of CDDP in non-small cell lung cancer. Anticancer Res 15 (1995), 2691–2695.
18. Koizumi, W, Tanabe, S, Saigenji, K, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89 (2003), 2207–2212.
19. Fukushima, M, Sakamoto, K, Sakata, M, et al. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep 24 (2010), 1307–1313.
20. Takagi, M, Sakata, K, Someya, M, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol 96 (2010), 259–266.
21. Therasse, P, Arbuck, SG, Eisenhauer, EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000), 205–216.
22. Vokes, EE, Herndon, JE II, Crawford, J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20 (2002), 4191–4198.
23. Vokes, EE, Herndon, JE II, Kelley, MJ, et al., Cancer and Leukemia Group B, Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007), 1698–1704.
24. Hanna, N, Neubauer, M, Yiannoutsos, C, et al., Hoosier Oncology Group, US Oncology, Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26 (2008), 5755–5760.
25. Ohyanagi, F, Yamamoto, N, Horiike, A, et al. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 101 (2009), 225–231.
26. Ichinose, Y, Kato, H, Koike, T, et al., Japanese Clinical Oncology Group, Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg 122 (2001), 803–808.
27. Segawa, Y, Kiura, K, Takigawa, N, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28 (2010), 3299–3306.
28. Yamamoto, N, Nakagawa, K, Nishimura, Y, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28 (2010), 3739–3745.